Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study

被引：0

作者：

Pasello, G. ^{[1
,2
]}

Lorenzi, M. ^{[1
,2
]}

Crivellaro, G. ^{[3
]}

Capelletto, E. ^{[4
]}

Buttice, S. ^{[4
]}

Perrone, F. ^{[5
]}

Tiseo, M. ^{[5
,6
]}

Scotti, V. ^{[7
]}

Polo, V. ^{[8
]}

Favaretto, A.

Montrone, M. ^{[9
]}

Berardi, R. ^{[10
]}

Zustovich, F. ^{[11
]}

Toschi, L. ^{[12
]}

Bearz, A. ^{[13
]}

Milella, M. ^{[14
]}

Frega, S.

Bonanno, L. ^{[3
]}

Guarneri, V. ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] IOV Ist Oncol Veneto IRCCS, Padua, Italy

[3] IOV Ist Oncol Veneto IRCCS, Oncol 2, Padua, Italy

[4] Azienda Osped Univ San Luigi Gonzaga, Dept Oncol, Orbassano, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Univ Parma, Dept Med & Surg, Parma, Italy

[7] AOUC Azienda Osped Univ Careggi, Dipartimento Oncol, Florence, Italy

[8] Osped Reg Ca Foncello, AULSS2 Dept Med Specialist, Treviso, Italy

[9] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Dipartimento Area Med, Bari, Italy

[10] AOU Osped Riuniti Umberto 1 GM Lancisi G Salesi, Dept Internal Med, Clin Oncol, Torrette Di Ancona, Italy

[11] Osped Belluno, Belluno, Italy

[12] Ist Clin Humanitas, Med Oncol Dept, Rozzano, Italy

[13] Ctr Riferimento Oncol CRO, Med Oncol, Aviano, Italy

[14] Univ Verona, Med Oncol 1, Fac Med, Verona, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

21P

引用

页码：S52 / S53

页数：2

共 50 条

[31] NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy
Kauffmann-Guerrero, Diego
Huber, Rudolf Maria
Reu, Simone
Tufman, Amanda
Mertsch, Pontus
Syunyaeva, Zulfiya
Jung, Andreas
Kahnert, Kathrin
RESPIRATION, 2018, 95 (03) : 169 - 176
[32] Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program
Ehmann, M.
Wannesson, L.
Pless, M.
Frueh, M.
Gautschi, O.
Curioni-Fontecedro, A.
Betticher, D.
Mark, M.
Ochsenbein, A.
Rothschild, S. I.
ANNALS OF ONCOLOGY, 2017, 28
[33] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Tao Jiang
Pingyang Wang
Jie Zhang
Yanqiu Zhao
Jianying Zhou
Yun Fan
Yongqian Shu
Xiaoqing Liu
Helong Zhang
Jianxing He
Guanghui Gao
Xiaoqian Mu
Zhang Bao
Yanjun Xu
Renhua Guo
Hong Wang
Lin Deng
Ningqiang Ma
Yalei Zhang
Hui Feng
Sheng Yao
Jiarui Wu
Luonan Chen
Caicun Zhou
Shengxiang Ren
Signal Transduction and Targeted Therapy, 6
[34] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Jiang, Tao
Wang, Pingyang
Zhang, Jie
Zhao, Yanqiu
Zhou, Jianying
Fan, Yun
Shu, Yongqian
Liu, Xiaoqing
Zhang, Helong
He, Jianxing
Gao, Guanghui
Mu, Xiaoqian
Bao, Zhang
Xu, Yanjun
Guo, Renhua
Wang, Hong
Deng, Lin
Ma, Ningqiang
Zhang, Yalei
Feng, Hui
Yao, Sheng
Wu, Jiarui
Chen, Luonan
Zhou, Caicun
Ren, Shengxiang
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[35] THE EFFICACY OF VANDETANIB, A DUAL INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES IN PREVIOUSLY TREATED ADVANCED NSCLC: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Zhou, G-W
Li, Q.
RESPIROLOGY, 2011, 16 : 171 - 172
[36] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
Guttman-Yassky, Emma
Mita, Alain
De Jong, Maja
Matthews, Lesley
McCarthy, Sean
Iwata, Kenneth K.
Verweij, Jaap
Rowinsky, Eric K.
Krueger, James G.
EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
[37] Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor
Park, K.
Ciardiello, F.
Hida, T.
Lim, W.
Lin, C-C.
Murakami, H.
Nishio, M.
Cantero, F.
Cattan, V.
Gabarroca, C.
Gandossi, E.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2017, 28
[38] MONITORING EGFR T790M WITH PLASMA DNA IN LUNG CANCER PATIENTS TREATED WITH EGFR TYROSINE KINASE INHIBITOR IN PROSPECTIVE OBSERVATIONAL STUDY
Aoe, Keisuke
Sueoka-Aragane, Naoko
Katakami, Nobuyuki
Satouchi, Miyako
Yokota, Soichiro
Iwanaga, Kentaro
Kimura, Shinya
Negoro, Shunichi
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S287 - S287
[39] ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE
Felip, Enriqueta
Hernandez-Losa, Javier
Murtra-Garrell, Nuria
Freixinos, Victor
Salcedo, Maite
Tallada, Natalia
Teixido, Cristina
Martinez, Pablo
Cedres, Susana
Lopez, Eva
Pandielle, Anastasio
Cajal, Santiago Ramon Y.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1104 - S1105
[40] Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma
Tambo, Yuichi
Sone, Takashi
Kasahara, Kazuo
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E199 - E200

← 1 2 3 4 5 →